What low-GWP propellants mean for inhaler design, manufacturing, and packaging.

Please provide your email address to receive an email when new articles are posted on . Risk for first moderate/severe COPD exacerbation was lower among dry powder vs. metered-dose or soft mist ...

GoodRx reports that choosing the right asthma inhaler depends on symptom severity and frequency, with options for quick ...

Zydus Lifesciences Limited (Zydus), an innovation-led life-sciences company with an international presence, has launched Aerolife Mini, a next-generation pMDI enhancer marking a significant step in ...

Patients who received fluticasone furoate-vilanterol had a 9% lower risk for a first moderate or severe COPD exacerbation than those who received budesonide-formoterol (hazard ratio [HR], 0.91; 95% CI ...

Extrafine single-inhaler triple therapy with BDP/FF/GB is effective for improving health-related quality of life and lung function in COPD.

AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...

Pulmonary Drug Delivery Technology Market Overview: The global pulmonary drug delivery technology market is projected to grow at a CAGR of approximately 5% over the next five years. This growth is ...

The impact of pulmonary diseases on other chronic conditions is often misunderstood and commonly underreported. More than half the Americans with Chronic Obstructive Pulmonary Disease (COPD) have not ...

Results from 2 COPD phase 3 trials suggest that targeting the IL-33 pathway with tozorakimab delivers meaningful clinical benefit.

Select your location to view local American Lung Association events and news near you.